28 related articles for article (PubMed ID: 25567592)
1. Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
July J; Patricia D; Gunawan PY; Setiajaya H; Ginting TE; Putra TP; Wuisan Z; Budhiarko D; Masykura N; Prayogi G; Utomo AR; Tandean S; Loe ML
Pan Afr Med J; 2020; 36():309. PubMed ID: 33282092
[TBL] [Abstract][Full Text] [Related]
2. Diffusion Kurtosis Imaging Reflects Glial Fibrillary Acidic Protein (GFAP), Topo IIα, and O⁶-Methylguanine-DNA Methyltransferase (MGMT) Expression in Astrocytomas.
Wang XC; Lei Y; Wang L; Tan Y; Qin JB; Ma GL; Zhang H
Med Sci Monit; 2018 Dec; 24():8822-8830. PubMed ID: 30520434
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
[TBL] [Abstract][Full Text] [Related]
4. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
5. Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma.
Carlos-Escalante JA; Gómez-Flores-Ramos L; Bian X; Perdomo-Pantoja A; de Andrade KC; Mejía-Pérez SI; Cacho-Díaz B; González-Barrios R; Reynoso-Noverón N; Soto-Reyes E; Sánchez-Correa TE; Guerra-Calderas L; Yan C; Chen Q; Castro-Hernández C; Vidal-Millán S; Taja-Chayeb L; Gutiérrez O; Álvarez-Gómez RM; Gómez-Amador JL; Ostrosky-Wegman P; Mohar-Betancourt A; Herrera-Montalvo LA; Corona T; Meerzaman D; Wegman-Ostrosky T
Cell Mol Neurobiol; 2021 Aug; 41(6):1285-1297. PubMed ID: 32535722
[TBL] [Abstract][Full Text] [Related]
6. IDH1-mutated Crohn's disease-associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated-type dysplasia.
Guerini C; Furlan D; Ferrario G; Grillo F; Libera L; Arpa G; Klersy C; Lenti MV; Riboni R; Solcia E; Fassan M; Mastracci L; Ardizzone S; Moens A; De Hertogh G; Ferrante M; Graham RP; Sessa F; Paulli M; Di Sabatino A; Vanoli A
Histopathology; 2024 Feb; 84(3):515-524. PubMed ID: 37988281
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma.
Tateishi K; Miyake Y; Nakamura T; Iwashita H; Hayashi T; Oshima A; Honma H; Hayashi H; Sugino K; Kato M; Satomi K; Fujii S; Komori T; Yamamoto T; Cahill DP; Wakimoto H
Acta Neuropathol Commun; 2023 Nov; 11(1):186. PubMed ID: 38012788
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Immunohistochemical Expression of MTAP and AKIP1 in IDH1 Mutant Astrocytoma.
Ahmed MM; Lateef MA; Elwan A; Fouad EM; Elsayed DH; Abdelnour HM; Abdullatif A
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3875-3882. PubMed ID: 38019246
[TBL] [Abstract][Full Text] [Related]
9. MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.
Liu L; Zhang KN; Zhao Z; Li G; Chai RC; Li Z; Liu X; Chen J; Jiang T
Brain Pathol; 2024 May; 34(3):e13198. PubMed ID: 37530224
[TBL] [Abstract][Full Text] [Related]
10. Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study.
Liu J; Zhang H; Zhang J; Bing Z; Wang Y; Li Q; Yang K
PeerJ; 2021; 9():e11350. PubMed ID: 34026352
[TBL] [Abstract][Full Text] [Related]
11. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
[TBL] [Abstract][Full Text] [Related]
12. Gliomatosis cerebri: Prognosis based on current molecular markers.
Maharaj MM; Phan K; Xu J; Fairhall J; Reddy R; Rao PJV
J Clin Neurosci; 2017 Sep; 43():1-5. PubMed ID: 28539209
[TBL] [Abstract][Full Text] [Related]
13. Supratentorial grade II astrocytoma: biological features and clinical course.
Wessels PH; Weber WE; Raven G; Ramaekers FC; Hopman AH; Twijnstra A
Lancet Neurol; 2003 Jul; 2(7):395-403. PubMed ID: 12849117
[TBL] [Abstract][Full Text] [Related]
14. [IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
Jiang M; Dong X; Li J; Li J; Qi J
Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):668-72. PubMed ID: 25567592
[TBL] [Abstract][Full Text] [Related]
15. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
